Clinical Professionals aim to be aware of the latest industry events and news whilst also aspiring to be at the forefront of the latest analytics and reporting. As a result we have collaborated with Vacancysoft to create monthly reports that provide an in-depth analysis of vacancies across various sectors, countries and companies. The latest CPIA
French bionic vision system firm, Pixium Vision has received approval from UK’s MHRA to start a clinical trial for patients who have lost sight due to retinitis pigmentosa (a group of inherited conditions that lead to a gradual reduction in vision) with the IRIS II bionic vision system.
Clinical Professionals will be exhibiting at the DIA Annual EuroMeeting on stand B10 in Hamburg on April 6th to 8th. The DIA is a global forum for exchanging knowledge to encourage innovation that will raise the level of health and wellbeing across the world. It was first founded in 1964 as a neutral global membership
Regulatory Professionals, part of the Clinical Professionals Group, is attending the Annual TOPRA Symposium in Berlin on the 12th – 14th of October. Aman and Angelo will be exhibiting at stand 8 this year. TOPRA is the professional membership organisation for those working within the regulatory affairs industry. The symposium is a unique and valuable
US regulatory body, the Food and Drug Administration (FDA), have granted breakthrough therapy status to Bristol-Myers Squibb and AbbVie’s elotuzumab to treat multiple myeloma (MM). The designation has been granted by the FDA for elotuzumab’s use with lenalidomide and dexamethasone in patients who have previously received one or more therapies to treat multiple myeloma. Elotuzumab
The National Institute for Health and Care Excellence (NICE) today published draft regulatory guidance rejecting Bayer’s Xofigo for patients with prostate cancer. Xofigo has been submitted to the regulatory body to treat patients with hormone relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases. Clinical trials have demonstrated that Xofigo can significantly improve
Epilepsy patients in Germany may gain access to Eisai’s drug, Fycompa, again after Germany’s Federal Joint Committee agreed to take another look at the drug’s pricing. Last year, Eisai announced that they would be withdrawing Fycompa (perampanel) from the German market as opposed to selling the epilepsy drug at the price approved by the Germany’s
Advisors for the US regulatory body, the FDA, have given strong support for the approval of Merck & Co’s bloodthinner drug, vorapaxar. The US regulatory agency’s Cardiovascular and Renal Drugs Advisory Committee yesterday voted 10-1 in favour of vorapaxar being allowed onto the US market as an adjunctive treatment for cutting atherothrombotic events in patients
US regulatory body, the Food and Drug Administration (FDA), have announced that they will be undertaking an accelerated a review of Sanofi’s Genzyme unit’s Gaucher disease drug, Cerdelga (eliglustat), having granted a six-month priority review for the application. Gaucher disease is a genetic disorder where lipids build up in cells and certain organs, causing problems
The US Food and Drug Administration (FDA) announced on Friday that they have approved Auxilium Pharmaceuticals’ Xiaflex to treat Peyronie’s disease, which causes painful, curved erections in men. Xiaflex (collagenase clostridium histolyticum) is the first FDA-approved non-surgical treatment option for men with Peyronie’s disease, who have a plaque in the penis that results in curvature
